NCT02555371

Trial name or title	Cessation versus continuation of long‐term mepolizumab in severe eosinophilic asthma patients
Methods	Multi‐center, randomised, double‐blind, placebo‐controlled, parallel‐group study
Participants	300 participants Asthma is currently being treated with a controller medication and the participant has been on a controller medication for the past 12 weeks. Participants will be expected to continue controller therapy for the duration of the study. Male or eligible female participants
Interventions	Mepolizumab 100 mg versus placebo
Outcomes	Primary outcome measures Time to first clinically significant exacerbation )(time frame: up to 52 week)] Secondary outcome measures Ratio to baseline in blood eosinophil count (time frame: baseline (week 0) and up to week 52) Time to a decrease in asthma control, defined as an increase from baseline in Asthma Control Questionnaire‐5 (ACQ‐5) score of ≥ 0.5 units Time to first exacerbation requiring hospitalisation or ED visit (time frame: up to 52 weeks)
Starting date	January 2016
Contact information	US GSK Clinical Trials Call Center GSKClinicalSupportHD@gsk.com
Notes	Estimated study completion date: January 2019